Assertion Supported AI assessment confidence: 95% certainty 4/5 debate potential 1/5

Nodelman: Aktis Oncology's IPO was 18x oversubscribed, backstopped by Eli Lilly

Oleg Noodleman · All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live · Jun 12, 2026 · at 31:38

Oleg Nodelman of EcoR1 Capital details Aktis Oncology's IPO metrics and strategic investor backing.

0:00 / 0:12exact quote · 12.5s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“Actis was started five years ago, but recently went public with a three hundred million dollar IPO that was 18 times oversubscribed, and backstopped with a hundred million dollar order by Eli Lilly, the folks who bring you all the weight loss drugs.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Aktis Oncology's $300 million IPO was 18 times oversubscribed and backstopped by a $100 million order from Eli Lilly.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim is accurate across all three stated details: 1) SEC filings (Form S-1/A and Form 424B4) confirm that Aktis Oncology targeted a $300 million raise (pricing at $318 million gross proceeds); 2) SEC filings and official press releases confirm Eli Lilly placed an indication of interest to purchase up to $100 million of shares in the offering; 3) Lead venture investor MPM BioImpact publicly confirmed the offering was 18 times oversubscribed (a standard order-book metric not typically listed in SEC filings).

Aktis Oncology SEC Form S-1/A and Form 424B4 confirmed a $300 million target raise ($318 million final gross proceeds).
SEC filings and official company releases confirmed an indication of interest/backstop of up to $100 million from Eli Lilly.
Statements from lead investor MPM BioImpact confirmed the IPO order book was 18 times oversubscribed.

Checked against

[1] aktisoncology.com [2] iposcoop.com [3] aktisoncology.com [4] renaissancecapital.com [5] investing.com [6] tradingview.com [7] sec.gov [8] drugdiscoverytrends.com

Aktis Oncology Eli Lilly 100 million oversubscribed Aktis Oncology 300 million 18 times oversubscribed Aktis Oncology IPO 300 million Eli Lilly Aktis Oncology SEC filing IPO S 1 424B4 "18x oversubscribed" "Aktis"

assessed as of 2026-07-30

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

Aktis Oncology Eli Lilly

⚑ Spot an error? Report it

More from Oleg Noodleman

Prediction Not checkable as stated

Nodelman: Aktis Oncology could reach a $10B valuation if one program succeeds

“We think Actis could be worth ten billion or 200 dollars per share if even one of their programs makes it to market, and in this case, you have a lot of outs.”

Oleg Noodleman Jun 12, 2026 ▶ 34:33 All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live

Prediction Not checkable as stated

Nodelman: Average human lifespan in developed countries will exceed 100 years

“I would take the over on that.”

Oleg Noodleman Jun 12, 2026 ▶ 37:49 All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live

Nodelman: Aktis Oncology's IPO was 18x oversubscribed, backstopped by Eli Lilly

More from Oleg Noodleman

Turn any episode into a week of clips.